Extended-dose Chloroquine (ECQ) for Resistant Falciparum Malaria Among Afghan Refugees in Pakistan (ECQNWFP)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01019408 |
Recruitment Status :
Completed
First Posted : November 25, 2009
Last Update Posted : November 25, 2009
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Malaria, Falciparum | Drug: Chloroquine | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 163 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Clinical Trial of Extended-dose Chloroquine Versus Standard Chloroquine Treatment for Resistant Falciparum Malaria Among Afghan Refugees in NWFP Pakistan |
Study Start Date : | November 1993 |
Actual Primary Completion Date : | January 1995 |
Actual Study Completion Date : | January 1995 |

Arm | Intervention/treatment |
---|---|
Active Comparator: CQ25
Falciparum positive patients receiving standard 3-day treatment course of CQ 25mg/kg.
|
Drug: Chloroquine
Comparison of two different dosages of chloroquine for treatment of falciparum malaria in Afghan refugee camps in Northwest Frontier Province, Pakistan
Other Name: CQ |
Active Comparator: CQ40
Falciparum positive patients receiving a 5-day treatment course of CQ 40 mg/kg.
|
Drug: Chloroquine
Comparison of two different dosages of chloroquine for treatment of falciparum malaria in Afghan refugee camps in Northwest Frontier Province, Pakistan
Other Name: CQ |
- therapeutic and parasitological cure with no recrudescence [ Time Frame: 60 days ]
- parasite clearance time [ Time Frame: 28 days ]
- fever clearance time [ Time Frame: 28 days ]
- gametocytaemia [ Time Frame: 28 days ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 6 Months to 60 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- slide-confirmed infection with P. falciparum only
- initial parasite density of 1000-100,000 asexual parasites/μl
- absence of severe malnutrition
- ability to attend stipulated follow-up visits and easy access to facility
- informed consent provided by patient or parent/guardian
- absence of history of hypersensitivity reactions to CQ
Exclusion Criteria:
- infants under six months old
- pregnancy or lactation
- underlying chronic severe illness
- patients with other febrile illnesses
- parasitaemia outside the range of 1000-100,000 asexual parasites/µl
- severe malaria

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01019408
Pakistan | |
Adezai Basic Health Unit | |
Adezai, Nwfp, Pakistan | |
Baghicha Basic Health Unit | |
Baghicha, Nwfp, Pakistan | |
Kagan Basic Health Unit | |
Kagan, Nwfp, Pakistan |
Principal Investigator: | Mark Rowland, PhD | LSHTM |
Responsible Party: | Mark Rowland, LSHTM |
ClinicalTrials.gov Identifier: | NCT01019408 History of Changes |
Other Study ID Numbers: |
NH-HNI01 |
First Posted: | November 25, 2009 Key Record Dates |
Last Update Posted: | November 25, 2009 |
Last Verified: | November 2009 |
Keywords provided by London School of Hygiene and Tropical Medicine:
Clinical Trial Chloroquine Refugees Afghanistan Pakistan |
Additional relevant MeSH terms:
Malaria Malaria, Falciparum Protozoan Infections Parasitic Diseases Chloroquine Chloroquine diphosphate Amebicides Antiprotozoal Agents Antiparasitic Agents Anti-Infective Agents Antimalarials |
Antirheumatic Agents Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Inflammatory Agents Filaricides Antinematodal Agents Anthelmintics |